Zenodo (CERN European Organization for Nuclear Research)
November 18, 2025
Parker Singleton, Mathias Harrer, Brooke Sevchik
A meta-analytic dataset on psilocybin-assisted therapies for adults with depressive symptoms is described. It compares psilocybin therapy against control conditions, providing effect sizes for outcomes at post-test and long-term follow-ups. The dataset follows the Metapsy data standard, with information independently extracted by two researchers and risk of bias assessed using the Cochrane Collaboration Risk of Bias Tool (Version 2). It is part of the living Sypres Collaboration database.
Zenodo (CERN European Organization for Nuclear Research)
November 18, 2025
Gevorgyan, Natalya, Gevorgyan, Narek
An analysis of over 19,000 Reddit posts across 40 psychology-related topics, using engagement metrics from more than 400,000 upvotes and comments, reveals that trauma, unsafe relationships, emotional exhaustion, and unmet needs for healing dominate public discourse. Trauma-related posts receive the highest engagement, indicating widespread distress rather than popularity-driven interest. The findings are contextualized within contemporary psychedelic research, suggesting that structured, sacred psilocybin practice—as used in The Magic Church framework—aligns with peer-reviewed evidence supporting emotional regulation, reduction in depressive symptoms, and increased meaning-making when conducted in safe, guided settings. The brief highlights both the societal burden of psychological suffering and the potential for ethically grounded, spiritually informed psychedelic practice to address unmet needs for healing, integration, and community support.
Zenodo (CERN European Organization for Nuclear Research)
November 16, 2025
Mathias Harrer, Parker Singleton, Brooke Sevchik
A meta-analytic research dataset on psilocybin-assisted therapies for adults with depressive symptoms has been created as part of the Metapsy project. The dataset includes comparisons of psilocybin therapy against control conditions, with effect sizes for outcomes at post-test and long-term follow-ups. Information was independently extracted by two researchers, and risk of bias was assessed using the Cochrane Risk of Bias Tool (Version 2).
Zenodo (CERN European Organization for Nuclear Research)
November 4, 2025
Bertocchi, Uri, Schwartz, Amit, Umschweif, Gali et al.
Psilocybin, a serotonergic psychedelic, produces long-lasting antidepressant effects, but the underlying mechanisms are not fully understood. This study examined epigenetic changes in the mouse brain after psilocybin treatment. Male C57BL/6 mice received either psilocybin or saline, and after 72 hours, DNA from the prefrontal cortex was analyzed using nanopore sequencing. The results showed 1,404 regions with altered 5-hydroxymethylcytosine (5hmC) levels, strongly enriched in the glutamatergic synapse pathway. In contrast, only 51 regions of altered 5-methylcytosine (5mC) were found, with no pathway enrichment. These findings suggest that psilocybin rapidly induces epigenetic modifications primarily through 5hmC, which may contribute to its sustained antidepressant effects and offer new targets for treating major depressive disorder.
Zenodo (CERN European Organization for Nuclear Research)
December 17, 2024
University Medical Center Groningen
A clinical trial called PsyPal, which tests psilocybin-assisted therapy for psychological distress in palliative care, has received medical ethical authorization under EU regulations, with conditions, in participating member states. The multi-site study involves 19 partners across nine European countries and is coordinated by the University Medical Centre Groningen. It will evaluate the safety and efficacy of psilocybin therapy for patients with progressive, incurable diseases such as COPD, multiple sclerosis, ALS, and atypical Parkinsonism and advanced Parkinson's disease. The announcement clarifies the regulatory status and outlines next steps before patient recruitment begins.
Zenodo (CERN European Organization for Nuclear Research)
July 25, 2023
Leonardo C. Olyachim
This paper explores the mathematical properties of an operator M̂, building on prior algebraic work. It focuses on events with two outcomes, labeled |1〉 and |2〉. The eigenvalue problem for M̂ⁿ is considered, and spectral decomposition yields a linear combination representation. The effect of multiple M̂ operators acting on the same state is examined, revealing that if outcomes are uncorrelated or have equal magnitude, the commutator is zero. For multiple intents, the total eigenvalue of an eigenvector equals the product of individual eigenvalues, resembling a superposition-like effect. The order of intents does not matter when generated simultaneously during a probabilistic event. Future directions include analyzing correlation coefficients, decomposing M̂ into infinitesimal operators, and studying dynamical state evolution.
Zenodo (CERN European Organization for Nuclear Research)
July 23, 2023
Leonardo C. Olyachim
The author introduces an algebraic framework for working with the equations of CMT, presenting an operator that represents magick intent and extending the treatment to cases where multiple such operators act on the same state or event.
Zenodo (CERN European Organization for Nuclear Research)
May 30, 2023
No Summary
Zenodo (CERN European Organization for Nuclear Research)
May 7, 2023
The text explains that refrigerating certain products, especially after opening, can extend their shelf life and maintain optimal viability for longer periods, leading to higher success rates when attempting to cultivate them at home.
Zenodo (CERN European Organization for Nuclear Research)
March 11, 2023
Parker Emmerson
The golden ratio plays a role in the digital harmonies of psilocybin when analyzed within a virtual logic-based vector space derived from the Geometry of Logic. This space, called Logic Space, enables the notation and analysis of chemical compounds and their behaviors in virtual neural nets.
Zenodo (CERN European Organization for Nuclear Research)
January 1, 2023
Cunningham, Michael
A presentation by Michael Cunningham describes the pharmacological mechanism of Ariadne, a non-hallucinogenic 5-HT2A agonist, and its analogs. The work focuses on how these compounds interact with the 5-HT2A receptor to produce biological activity without inducing hallucinogenic effects, distinguishing their mechanism of action from classic psychedelics. The research explores the chemistry and biological activity of these molecules, contributing to understanding of agonist-antagonist dynamics in drug development.
Zenodo (CERN European Organization for Nuclear Research)
January 1, 2023
Sameš, Dalibor
Ibogaine, a psychoactive alkaloid, is being investigated for its potential to treat substance use disorders. The abstract reports an update on ibogaine presented at a 2023 conference in Prague, but provides no specific findings, data, or conclusions about its efficacy or mechanisms.
Zenodo (CERN European Organization for Nuclear Research)
November 21, 2022
Magic mushrooms, typically containing psilocybin, are psychoactive fungi that act as psychedelic medications. When ingested, they alter sensory perception, reasoning, and thoughts, often producing vivid closed- and open-eye hallucinations, along with feelings of euphoria and well-being.
Zenodo (CERN European Organization for Nuclear Research)
November 21, 2022
Magic mushrooms, which typically contain psilocybin, are psychoactive fungi that can alter thinking, feelings, and sensory experiences. When ingested, they often produce vivid hallucinations, closed- and open-eye visuals, and feelings of euphoria and well-being. The text describes these substances as psychedelic medications that influence most of the senses.
Zenodo (CERN European Organization for Nuclear Research)
October 29, 2022
Magic mushrooms are psychoactive fungi, most commonly those containing psilocybin, and they are particularly popular in British Columbia. The text defines the term and notes its regional popularity without presenting any empirical findings or arguments.
Zenodo (CERN European Organization for Nuclear Research)
July 16, 2022
Magic mushrooms reduce stress and distress primarily through inducing feelings of affection and a sense of oneness. This leads to changes in the brain, known as brain adaptability. MRI imaging studies show that psilocybin alters brain activity, enabling communication between brain regions that do not normally interact, which is considered important for the breakthroughs people report.
Zenodo (CERN European Organization for Nuclear Research)
May 13, 2022
Liliana Irizabal
A systematic review of published research indicates that psychedelic psychotherapy can reduce symptoms of depression, anxiety, and PTSD. Psilocybin and ayahuasca (DMT) were associated with decreased anxiety and depression when administered in specific doses. MDMA was associated with reduced PTSD symptoms. The authors note that research is limited and more studies are needed, but the existing evidence shows promising results.
Zenodo (CERN European Organization for Nuclear Research)
April 3, 2022
Van der Sypt Frederick A.p.
An accessible procedure called MESQ (Microscale Extraction followed by Scanometric Quantitative thin-layer chromatography) was validated for measuring mescaline in live cactus tissue and aqueous extracts. The method was tested on Lophophora williamsii (peyote) and three Echinopsis species. It revealed a previously unknown radial mescaline gradient in L. williamsii and a longitudinal gradient in Echinopsis species. A predictable correlation appeared between mescaline concentration in targeted biopsies and overall cactus strength. The procedure supports selective propagation of mescaline-rich specimens to protect wild populations and helps users dose extracts accurately, contributing to harm reduction for both the cacti and their users.
Zenodo (CERN European Organization for Nuclear Research)
December 18, 2021
Harriet A. Carroll
MDMA (ecstasy) caused blood sugar dysregulation and high insulin levels in two female scientists who tested it on themselves, compared to a no-drug control day. The drug raised the stress hormone cortisol in both, but only one showed an increase in copeptin (a marker of the water-balance hormone AVP). That same person produced less urine, felt thirstier, and had a drier mouth. Because glucose problems occurred without consistent AVP elevation, cortisol—not AVP—is likely the main driver. The findings are preliminary and need replication in larger, therapeutic-style studies.
Zenodo (CERN European Organization for Nuclear Research)
May 20, 2021
Ibogaine, a natural alkaloid from the African Tabernanthe iboga shrub, is used to treat addiction to substances such as heroin, cocaine, and alcohol. It removes withdrawal symptoms and addresses underlying factors like depression, anxiety, and stress. The product is offered in various forms including root bark, powder, and HCl, sourced from Cameroon and Gabon. Its traditional use in Central African ceremonies for healing and initiation is noted. The treatment is described as safe, effective, and affordable, with the goal of resetting neurotransmitters and facilitating psychological and spiritual transformation through introspective experiences.
Zenodo (CERN European Organization for Nuclear Research)
August 31, 2019
Manca Peskar
In treatment-resistant depression, openness to experience and its neural correlates were examined before and after a psilocybin-assisted intervention. The study aimed to extend personality neuroscience findings from healthy individuals to depressed populations and to uncover neural mechanisms that might mediate clinical improvements. The results suggest that changes in openness are linked to specific brain activity patterns, potentially underlying therapeutic benefits.